Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more

TSXV:XRTX - Post Discussion

XORTX Therapeutics Inc > This news should have 50% gain
View:
Post by moneywinner1 on Jun 06, 2022 11:23am

This news should have 50% gain

Huge change in the board
Comment by moneywinner1 on Jun 06, 2022 12:11pm
Shareholders were waiting for this change , let's see it goes to new 52 week high, over $10 easy 
Comment by moneywinner1 on Jun 06, 2022 12:24pm
One year target just in on Nasdaq $17.50 USA dollars 
Comment by moneywinner1 on Jun 07, 2022 9:20am
All shareholders were expecting this addition to the company . Now news on USA drug approval and this is going well into target . $17.50 USA 
Comment by moneywinner1 on Jun 07, 2022 10:23am
Look at Nasdaq is up 9% already this morning, 
XORTX Therapeutics Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities